Multiplatform urinary metabolomics profiling to discriminate cachectic from non-cachectic colorectal cancer patients: Pilot results from the colocare study

Jennifer Ose, Biljana Gigic, Tengda Lin, David B. Liesenfeld, Jürgen Böhm, Johanna Nattenmüller, Dominique Scherer, Lin Zielske, Petra Schrotz-King, Nina Habermann, Heather M. Ochs-Balcom, Anita R. Peoples, Sheetal Hardikar, Christopher I. Li, David Shibata, Jane Figueiredo, Adetunji T. Toriola, Erin M. Siegel, Stephanie Schmit, Martin SchneiderAlexis Ulrich, Hans Ulrich Kauczor, Cornelia M. Ulrich

Research output: Contribution to journalArticle

Abstract

Cachexia is a multifactorial syndrome that is characterized by loss of skeletal muscle mass in cancer patients. The biological pathways involved remain poorly characterized. Here, we compare urinary metabolic profiles in newly diagnosed colorectal cancer patients (stage I-IV) from the ColoCare Study in Heidelberg, Germany. Patients were classified as cachectic (n = 16), pre-cachectic (n = 13), or non-cachectic (n = 23) based on standard criteria on weight loss over time at two time points. Urine samples were collected pre-surgery, and 6 and 12 months thereafter. Fat and muscle mass area were assessed utilizing computed tomography scans at the time of surgery. N = 152 compounds were detected using untargeted metabolomics with gas chromatography-mass spectrometry and n = 154 features with proton nuclear magnetic resonance spectroscopy. Thirty-four metabolites were overlapping across platforms. We calculated differences across groups and performed discriminant and overrepresentation enrichment analysis. We observed a trend for 32 compounds that were nominally significantly different across groups, although not statistically significant after adjustment for multiple testing. Nineteen compounds could be identified, including acetone, hydroquinone, and glycine. Comparing cachectic to non-cachectic patients, higher levels of metabolites such as acetone (Fold change (FC) = 3.17; p = 0.02) and arginine (FC = 0.33; p = 0.04) were observed. The two top pathways identified were glycerol phosphate shuttle metabolism and glycine and serine metabolism pathways. Larger subsequent studies are needed to replicate and validate these results.

Original languageEnglish
Article number178
JournalMetabolites
Volume9
Issue number9
DOIs
StatePublished - Sep 2019

Keywords

  • Cancer cachexia
  • Colorectal cancer
  • Metabolomics
  • Serial samples
  • Urinary profiles

Fingerprint Dive into the research topics of 'Multiplatform urinary metabolomics profiling to discriminate cachectic from non-cachectic colorectal cancer patients: Pilot results from the colocare study'. Together they form a unique fingerprint.

  • Cite this

    Ose, J., Gigic, B., Lin, T., Liesenfeld, D. B., Böhm, J., Nattenmüller, J., Scherer, D., Zielske, L., Schrotz-King, P., Habermann, N., Ochs-Balcom, H. M., Peoples, A. R., Hardikar, S., Li, C. I., Shibata, D., Figueiredo, J., Toriola, A. T., Siegel, E. M., Schmit, S., ... Ulrich, C. M. (2019). Multiplatform urinary metabolomics profiling to discriminate cachectic from non-cachectic colorectal cancer patients: Pilot results from the colocare study. Metabolites, 9(9), [178]. https://doi.org/10.3390/metabo9090178